The University of Maryland Institute for Health Computing hosted its inaugural lunch lecture and networking event Sept. 30 at its headquarters in North Bethesda. Dr. Charles Sneiderman, M.D., Ph.D, spoke about the history of health computing. #MPowerMD shha.re/NI4eZ

Weight Loss Medications Could Be Key In Lowering Obesity Rates In The US ⁦Rozalina (Grubina) McCoy, MD MS⁩ nybreaking.com/weight-loss-me…

🚨 #postdocs opportunity with my amazing team at the Univ. of Maryland / University of Maryland, Baltimore Institute for Health Computing ihc.umd.edu studying #diabetes management and outcomes post IRA. Need experience w/desire to learn claims. Ideally, T32 eligible

Our new BMJ paper on lower rates of two common, very painful conditions, kidney stones and gout flares, after initiation of SGLT2i: dual added benefits beyond diabetes. MGH Rheumatology & Allergy Clin Epi Research Mongan Institute MGH Rheumatology @MGH_RI Chio Yokose Deborah Wexler Rozalina (Grubina) McCoy, MD MS Arthritis Research Canada

An amazing opportunity in University of Maryland School of Medicine for aspiring physicians interested in working in rural areas of Maryland. This program includes mentorship, clinical practice, and research focused on supporting and caring for our rural communities.

🚨Exciting new statement from ADA on compounded GLP-1 RA and dual GIP and GLP-1 RA products🚨 Joshua Neumiller Mandeep Bajaj Rozalina (Grubina) McCoy, MD MS Nuha ElSayed, MD, MMSc diabetesjournals.org/care/article/d…

Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from American Diabetes Association - DiabetesPro diabetesjournals.org/care/article/d… Expert guidance lighting up a black out of information Joshua Neumiller Rozalina (Grubina) McCoy, MD MS Nuha ElSayed, MD, MMSc

Managing obesity in adults with type 1 diabetes pubmed.ncbi.nlm.nih.gov/39746549/ Diseases are changing its natural history - Type 1 diabetes phenotype is no longer "thinner people" disease Rozalina (Grubina) McCoy, MD MS Maryland Medicine

The rising prevalence of obesity in adults with type 1 diabetes (T1DM) has spurred innovative approaches to manage this dual challenge effectively. A recent comprehensive review outlines crucial updates that every clinician should know. Here are five key insights Rozalina (Grubina) McCoy, MD MS

Tune in for a glimpse of the many important and actionable updates in the 2025 ADA standards of care! American Diabetes Association American Diabetes Association - DiabetesPro University of Maryland School of Medicine University of Maryland Medical Center University of Maryland Medical System

💊Adults with type 2 #diabetes who use a #GLP1 may have a higher #thyroid cancer risk in the months after starting the medication compared with other drugs. Learn more about the findings ⬇️ Rozalina (Grubina) McCoy, MD MS JAMA Otolaryngology – Head & Neck Surgery University of Maryland School of Medicine HemOnc Today Healio healio.com/news/endocrino…

🩺 “Patients treated with #GLP1 receptor agonists are not more likely to develop #thyroid cancer, they are just more likely to be diagnosed with thyroid cancer because we (as clinicians) are more likely to look for it." - Rozalina (Grubina) McCoy, MD MS healio.com/news/endocrino…

Our study ja.ma/40IofZe found a ⬆️risk of thyroid cancer diagnosis within the 1 year of GLP-1RA initiation. But here's the catch—patients on GLPs had more thyroid ultrasounds. This suggests the link is due to increased detection rather than the drug causing new cancer🧵

Our latest research suggests GLP-1RA might not cause thyroid cancer but increase its detection during the first year of use: More ultrasounds than controls during the first year = more thyroid cancer diagnoses ja.ma/40IofZe Juan P Brito Rozalina (Grubina) McCoy, MD MS Mayo Clinic Endocrinology

Is there a link between GLP-1RA use & thyroid cancer? A study co-auther by EGDRC members, published in JAMA found a short-term association between GLP-1RA initiation and thyroid cancer diagnosis, likely due to increased vigilance in detection. 🔗 jamanetwork.com/searchresults?…

⭐️Best of #ClinicalDiabetesADA2024⭐️ | #20 ALTMETRIC Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk -Rozalina G. McCoy et al. doi.org/10.2337/cd24-0…

Join ADA professional members on Feb. 11, 2025, at 3:00 PM ET for the latest Hands-On webinar: Lifestyle, Medicine, and Beyond: CKM Strategies for Managing Obesity in People with T2D. Register now: bit.ly/4jwywPk Rozalina (Grubina) McCoy, MD MS Dina Hafez Griauzde Jaime Almandoz, MD MBA FTOS

🚨📢 Postdoc opening Emory Epidemiology in pharmaceutical regulation, evidence synthesis & meta-research. 1-year position w/ possible renewal. Formal posting coming soon—message or email me for details. Please share! Yale CRRIT METRICStanford Florian Naudet Research on Research Institute (RoRI) Joseph Ross

Download now - free accredited interactive infographics! Explore key considerations for integrating CGM in primary care, with practical guidance on patient selection, data interpretation, and effective patient communication. Download now: bit.ly/InfographicDow… #CGM #MedEd

Disparities in technology utilization among youth with type 1 diabetes (T1D) across diverse racial and socioeconomic backgrounds Rozalina (Grubina) McCoy, MD MS Learn more 👉 bit.ly/3ROk8FG